| Literature DB >> 16573811 |
Khaled K Abu-Amero1, Olayan M Al-Boudari, Gamal H Mohamed, Nduna Dzimiri.
Abstract
BACKGROUND: The role of the Beta2-adrenoceptor (beta2-AR) Gln27Glu polymorphism in the manifestation of cardiovascular diseases is still unclear.Entities:
Mesh:
Substances:
Year: 2006 PMID: 16573811 PMCID: PMC1481543 DOI: 10.1186/1471-2350-7-31
Source DB: PubMed Journal: BMC Med Genet ISSN: 1471-2350 Impact factor: 2.103
Genotypic and allelic distribution of the Gln27Glu polymorphism of β2-AR gene among angiographically confirmed coronary artery disease patients (CAD) and blood donors group (BD). CI, confidence interval
| C/C | 391 (50.6%) | 613 (68.5%) | - | reference | - |
| C/G | 337 (43.6%) | 253 (28.3%) | 2.09 | [1.69 – 2.58] | < .001 |
| G/G | 45 (5.8%) | 29 (3.2%) | 2.43 | [1.46 – 4.06] | < .001 |
| C | 1119 (72.4%) | 1479 (82.6%) | - | reference | - |
| G | 427 (27.6%) | 311 (17.4%) | 1.81 | [1.53 – 2.15] | < .001 |
Genotypic and allelic distribution of the Gln27Glu polymorphism of β2-AR gene among angiographically confirmed coronary artery disease patients (CAD) and angiographed controls (CON). CI, confidence interval
| C/C | 391 (50.6%) | 379 (71.8%) | - | reference | - |
| C/G | 337 (43.6%) | 129 (24.4%) | 2.53 | [1.97 – 3.24] | < .001 |
| G/G | 45 (5.8%) | 20 (3.8%) | 2.18 | [1.26 – 3.76] | .005 |
| C | 1119 (72.4%) | 887 (84.5%) | - | reference | - |
| G | 427 (27.6%) | 163 (15.5%) | 2.08 | [1.69 – 2.55] | < .001 |
Determination of odds ratio for the CAD risk factors among CAD and CON groups
| Genotype | C/C | 391 | 379 | reference | - | - |
| C/G | 337 | 129 | 2.53 | 1.96 – 3.27 | < .001 | |
| G/G | 45 | 20 | 2.18 | 1.23 – 3.90 | .004 | |
| Age | < 40 | 128 | 113 | reference | - | - |
| ≥ 40 | 645 | 415 | 1.37 | 1.03 – 1.84 | .027 | |
| Elevated Chol | No | 138 | 106 | reference | - | |
| Yes | 635 | 422 | 1.16 | 0.86 – 1.55 | .313 | |
| Elevated TG | No | 208 | 138 | reference | - | - |
| Yes | 565 | 390 | 1.19 | 0.91 – 1.56 | .188 | |
| DM | No | 375 | 306 | reference | - | - |
| Yes | 398 | 222 | 1.46 | 1.16 – 1.84 | < .001 | |
| FH | No | 540 | 372 | reference | - | - |
| Yes | 233 | 156 | 1.03 | 0.80 – 1.32 | .817 | |
| Gender | F | 296 | 230 | reference | - | - |
| M | 477 | 298 | 1.24 | 0.99 – 1.57 | .057 | |
| Hypertension | No | 86 | 60 | reference | - | - |
| Yes | 687 | 468 | 1.02 | 0.71 – 1.47 | .894 | |
| MI | No | 543 | 364 | reference | - | - |
| Yes | 230 | 164 | 0.94 | 0.73 – 1.20 | < .614 |
Chol, Cholesterol; DM, Diabetes Mellitus; FH, family history; MI, Myocardial infarction on admission; TG, Triglycerides. Elevated serum triglycerides (> 1.8 mmol/L); Elevated total cholesterol (> 5.2 mmol/L).
Stepwise multiple logistic regression results
| Genotype | 391 | C/C | reference | - | - |
| 337 | C/G | 2.5 | 1.79 – 3.49 | < .001 | |
| 45 | G/G | 3.18 | 1.66 – 6.05 | < .001 |